Legal Battle Tied To Guidant Saga Ends With Record Settlement, Probation
This article was originally published in The Gray Sheet
Executive Summary
The legal component of a long-running controversy over Guidant's past failures to disclose malfunction risks associated with implantable defibrillators largely came to a close Jan. 12.
You may also be interested in...
News Briefs: Boston Sci Settlement; C.R. Bard Scores Patent Victory
Boston Scientific owes another $30 million to settle more charges related to Guidant ICD issues. C.R. Bard closer to receiving big payout from Gore on patent case. FDA issues a safety alert on St. Jude’s Amplatzer occluder More news briefs.
News In Brief
Novartis buys Genoptix
News In Brief
Novartis buys Genoptix